Key result
Primary renal synovial sarcoma exhibits aggressive behavior linked to ~50% disease-related mortality.
Why the study?
Previous studies of primary renal synovial sarcoma were limited by small sample sizes, leaving clinical and molecular understanding incomplete.
Observational (n=70)
Yes
Primary renal synovial sarcoma is an aggressive tumor with high rates of metastasis and death, often characterized by SS18::SSX2 fusion, requiring molecular techniques for accurate diagnosis.
Indicates poor prognosis requiring molecular confirmation; leaves open prospective trials to define optimal management.
Synovial sarcoma is a rare malignant mesenchymal neoplasm that typically occurs in soft tissue sites, and the kidney is an uncommon primary location. Previous studies of primary renal synovial sarcoma are limited by small sample sizes, and our understanding remains incomplete. Here, we present the largest multi-institutional case series to date of primary renal synovial sarcoma, with a focus on novel and molecular findings. A total of 70 cases were contributed by multiple institutions. Comprehensive clinical and histopathologic data were collected and analyzed. The mean patient age was 40 years, with a male-to-female ratio of 1.9:1. The most common presenting signs and symptoms were pain and hematuria. The mean tumor size was 11.6 cm (range: 2.3 to 26 cm), with frequent cystic change and necrosis. The mean follow-up was 29 months (range: 2 to 129 mo), and the rates of metastasis, recurrence, and death due to disease were 62.7%, 33.3%, and 50.0%, respectively. Histologically, 56.1% were monophasic synovial sarcoma, 15.1% were biphasic, and 28.8% were poorly differentiated or showed round cell features. Molecularly, SS18::SSX2 fusion was detected in the majority of cases assessed (n=19), followed by SS18::SSX1 fusion (n=6) and a rare SS18::NEDD4 fusion (n=1). Given the morphologic and immunohistochemical overlaps with many other neoplasms, accurate diagnosis with preferably molecular techniques is crucial for appropriate prognostication and treatment of this aggressive tumor.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) conducted an observational in Primary renal synovial sarcoma (n=70). Primary renal synovial sarcoma was evaluated on Metastasis, recurrence, and death due to disease. Primary renal synovial sarcoma is an aggressive tumor with high rates of metastasis (62.7%), recurrence (33.3%), and death due to disease (50.0%) over a mean follow-up of 29 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: